Perry Hall, DO
Family Medicine · Fairmont, WVNPI 1083656896
Payments from drug & device makers
Across 164 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$712
- Abbott$319
- Amarin Pharma, Inc.$308
- Almatica Pharma LLC$271
- Mylan Specialty L.p.$254
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$172
- plus $651 from 19 others
What the payments were for
- Food & beverage$2,681100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $712 |
| Abbott | 15 | $319 |
| Amarin Pharma, Inc. | 30 | $308 |
| Almatica Pharma LLC | 12 | $271 |
| Mylan Specialty L.p. | 11 | $254 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $172 |
| Daiichi Sankyo Inc. | 6 | $97 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Antares Pharma, Inc. | 3 | $52 |
| Lilly USA, LLC | 3 | $46 |
| Novo Nordisk | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 2 | $43 |
| Lundbeck LLC | 2 | $38 |
| Johnson & Johnson | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $31 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Medtronic | 1 | $30 |
| Melinta Therapeutics, LLC | 2 | $30 |
| Smith+Nephew | 2 | $29 |
| Virtus Pharmaceuticals LLC | 1 | $24 |
| AstraZeneca | 1 | $20 |
| Merck | 1 | $14 |
| GSK | 1 | $13 |
| Novartis | 1 | $12 |
| Organogenesis Inc. | 1 | $7 |
How this compares
$2,688 in reported general payments places this provider in the 80th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $151,257 |
| EliquisApixaban | 90 | $89,484 |
| JardianceEmpagliflozin | 36 | $45,907 |
| JanuviaSitagliptin Phosphate | 44 | $29,426 |
| FarxigaDapagliflozin Propanediol | 20 | $28,534 |
| TradjentaLinagliptin | 27 | $21,218 |
| XareltoRivaroxaban | 20 | $16,379 |
| EntrestoSacubitril/Valsartan | 14 | $15,135 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $10,438 |
| MyrbetriqMirabegron | 21 | $10,073 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $9,791 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,948 |
| VascepaIcosapent Ethyl | 11 | $8,111 |
| LinzessLinaclotide | 15 | $7,580 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 398 | $7,389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $44 | $151,257107 claims |
| AstraZenecaFarxiga, Symbicort | $20 | $31,91733 claims |
| MerckJanuvia | $14 | $29,42644 claims |
| Johnson & JohnsonXarelto | $35 | $16,37920 claims |
| NovartisEntresto | $12 | $15,13514 claims |
| AbbVieLinzess, Synthroid | $712 | $9,53346 claims |
| GSKTrelegy Ellipta | $13 | $8,94812 claims |
| Smith+NephewSantyl | $29 | $3,26711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Fairmont
- Marilyn BonfiliFairmont$12K
- Lisa FlowerFairmont$11K
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
- Courtney PilkertonMorgantown$45K
- Isha WoofterClarksburg$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.